Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$70.30

1.73 (2.52%)

, MDCO

The Medicines Co.

$38.51

0.32 (0.84%)

17:07
10/05/16
10/05
17:07
10/05/16
17:07

Alnylam down 42% after drug development halt, Medicines Co. down 3.6%

ALNY

Alnylam

$70.30

1.73 (2.52%)

MDCO

The Medicines Co.

$38.51

0.32 (0.84%)

  • 14

    Oct

  • 06

    Nov

ALNY Alnylam
$70.30

1.73 (2.52%)

08/22/16
WEDB
08/22/16
NO CHANGE
WEDB
Intellia Therapeutics data positive, says Wedbush
Wedbush analyst David Nierengarten says that additional data on Intella's (NTLA) TTR program in mice was "meaningful" and indicates that the program compares favorably with competing products. The analyst says that competing programs, including those of Alnylam (ALNY) and Ionis (IONS) have shown "only a transient benefit." He reiterates a $38 price target and Outperform rating on Intella.
09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
09/15/16
09/15/16
INITIATION
Target $82

Underperform
FBR calls Alexion overvalued, starts shares at Underperform
FBR Capital analyst Christopher James initiated coverage of Alexion Pharmaceuticals (ALXN) with an Underperform rating and $82 price target. The biotech focused on patients with ultra-rare disorders closed yesterday up $2.63 to $129.42. Alexion shares are overpriced as the company is facing a competitive near-term landscape, particularly from Alnylam's (ALNY) ALN-CC5, James tells investors in a research note. Further, near-term expansion into additional indications will be challenging given the recent failed study with eculizumab in refractory generalized myasthenia gravis, the analyst contends. He also sees possible pricing pressures from biosimilars, including an Amgen (AMGN) biosimilar product in development. James this morning also initiated Achillion Pharmaceuticals (ACHN) and Arena Pharmaceuticals (ARNA) with Outperform ratings.
09/28/16
JANY
09/28/16
INITIATION
Target $74
JANY
Neutral
Alnylam initiated with a Neutral at Janney Capital
Janney Capital analyst Roy Buchanan initiated Alnylam with a Neutral and a $74 fair value estimate. The analyst is not confident about the outcome for the pivotal study for patisiran in transthyretin familial amyloid neuropathy, expected in about 12 months, and give patisiran a 50% chance of success.
MDCO The Medicines Co.
$38.51

0.32 (0.84%)

05/13/16
JEFF
05/13/16
NO CHANGE
Target $43
JEFF
Buy
The Medicines Co. could rally $4/share on positive data, says Jefferies
Jefferies analyst Biren Amin says The Medicines Co. has a "catalyst-rich" second half of 2016, including the Phase III trials of Carbavance in complicated urinary tract infections and carbapenem resistant enterobacteriaceae infections. The analyst expects both of the trials will be successful and show non-inferiority leading to potential FDA approval. Amin thinks shares could move $3 to $4 per share on positive data readout. He keeps a Buy rating on The Medicines Co. with a $43 price target.
07/11/16
JEFF
07/11/16
NO CHANGE
Target $43
JEFF
Buy
Jefferies views The Medicines Co. ruling as positive surprise
Jefferies analyst Biren Amin views today's Court of Appeals ruling as a "positive surprise" for The Medicines Company. The ruling "breathes potential life" into the company's Angiomax patents, Amin tells investors in a research note. He expects Hospira to file an appeal within 90 days. The analyst has a Buy rating on The Medicines Co. with a $43 price target.
08/02/16
EVER
08/02/16
NO CHANGE
EVER
Buy
Pfizer shelves oral PCSK9, a Medicines Co. competitor, says Evercore ISI
Evercore ISI analyst Umer Raffat said Pfizer (PFE) management does not thin the profile for oral PCSK9 will be competitive with the strong efficacy of antibodies and have moved other interesting products forward. Raffat said some Medicines Co. (MDCO) investors had worried that a potential oral PCSk9 from Pfizer could greatly reduce enthusiasm for an every-6-month PCSk9 from MDCO. The analyst said the next catalyst for The Medicines Co. is A1 Milano readout this month. Raffat rates The Medicines Co. a Buy with a $52 price target.

TODAY'S FREE FLY STORIES

PAC

GAP Airports

$102.12

0.45 (0.44%)

06:39
01/16/18
01/16
06:39
01/16/18
06:39
Earnings
GAP Airports sees FY18 total revenue growth 13%, plus or minus 1% »

FY18 revenue consensus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$18.76

-0.26 (-1.37%)

06:39
01/16/18
01/16
06:39
01/16/18
06:39
Hot Stocks
GE Capital to fund contributions, suspend dividend to GE for forseeable future »

GE Capital to fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

K

Kellogg

$64.69

-1.29 (-1.96%)

, CPB

Campbell Soup

$45.51

-0.24 (-0.52%)

06:39
01/16/18
01/16
06:39
01/16/18
06:39
Recommendations
Kellogg, Campbell Soup analyst commentary  »

Kellogg added to U.S.…

K

Kellogg

$64.69

-1.29 (-1.96%)

CPB

Campbell Soup

$45.51

-0.24 (-0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

GE

General Electric

$18.76

-0.26 (-1.37%)

06:39
01/16/18
01/16
06:39
01/16/18
06:39
Hot Stocks
GE to take $6.2B charge in Q4 on insurance operations »

GE announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

CPB

Campbell Soup

$45.51

-0.24 (-0.52%)

06:37
01/16/18
01/16
06:37
01/16/18
06:37
Upgrade
Campbell Soup rating change  »

Campbell Soup upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDX

Market Vector Gold Miners

$24.01

0.63 (2.69%)

06:36
01/16/18
01/16
06:36
01/16/18
06:36
Technical Analysis
Market Vector Gold Miners: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$126.96

1.52 (1.21%)

06:35
01/16/18
01/16
06:35
01/16/18
06:35
Technical Analysis
SPDR Gold Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EADSY

Airbus

$27.53

0.38 (1.40%)

06:34
01/16/18
01/16
06:34
01/16/18
06:34
Periodicals
Airbus prepared to shut down production of A380 superjumbo, FT reports »

Airbus is ready to shut…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUGT

Direxion Gold Miners Bull

$34.63

2.54 (7.92%)

06:34
01/16/18
01/16
06:34
01/16/18
06:34
Technical Analysis
Direxion Gold Miners Bull: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$18.81

1.47 (8.48%)

06:33
01/16/18
01/16
06:33
01/16/18
06:33
Technical Analysis
Direxion Daily Jr Gld Mnrs Bull 3X Shrs: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOXA

21st Century Fox

$36.73

0.53 (1.46%)

06:32
01/16/18
01/16
06:32
01/16/18
06:32
Upgrade
21st Century Fox rating change  »

21st Century Fox upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

DUST

Direxion Daily Gold Miners Bear 3X ETF

$21.30

-1.89 (-8.15%)

06:32
01/16/18
01/16
06:32
01/16/18
06:32
Technical Analysis
Direxion Daily Gold Miners Bear 3X ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SP

SP Plus Corp.

$38.00

0.2 (0.53%)

06:31
01/16/18
01/16
06:31
01/16/18
06:31
Hot Stocks
SP Plus Corp. sells joint venture interest in Parkmobile, sees Q1 gain »

SP Plus Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JDST

Direxion Daily Junior Gold Miners Index Bear 3x Shares

$47.10

-4.42 (-8.58%)

06:31
01/16/18
01/16
06:31
01/16/18
06:31
Technical Analysis
Direxion Daily Junior Gold Miners Index Bear 3x Shares: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VXX

iPath S&P 500 VIX Short-Term Futures

$25.85

0.01 (0.04%)

06:30
01/16/18
01/16
06:30
01/16/18
06:30
Technical Analysis
iPath S&P 500 VIX Short-Term Futures: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLB

Dolby

$65.35

1.06 (1.65%)

06:29
01/16/18
01/16
06:29
01/16/18
06:29
Downgrade
Dolby rating change  »

Dolby downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XIV

VelocityShares Daily Inverse VIX Short-Term ETN

$144.75

-0.25 (-0.17%)

06:29
01/16/18
01/16
06:29
01/16/18
06:29
Technical Analysis
VelocityShares Daily Inverse VIX Short-Term ETN: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

C

Citi

$76.84

1.28 (1.69%)

06:28
01/16/18
01/16
06:28
01/16/18
06:28
Periodicals
Citi results likely 'overwhelmed' by $20B charge due to tax overhaul, WSJ says »

Citigroup's results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

JPM

JPMorgan

$112.67

1.83 (1.65%)

06:28
01/16/18
01/16
06:28
01/16/18
06:28
Hot Stocks
JPMorgan reports December net credit losses 2.43% vs. 2.36% last month »

Reports December 30-plus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

TVIX

VelocityShares Daily 2x VIX Short-Term ETN

$4.74

0.01 (0.21%)

06:27
01/16/18
01/16
06:27
01/16/18
06:27
Technical Analysis
VelocityShares Daily 2x VIX Short-Term ETN: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INNV

Innovus Pharmaceuticals

06:27
01/16/18
01/16
06:27
01/16/18
06:27
Hot Stocks
Innovus Pharmaceuticals' hemorrhoid drug Xyralid approved in Canada »

Innovus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVXY

ProShares Short VIX Short-Term Futures

$138.19

-0.02 (-0.01%)

06:26
01/16/18
01/16
06:26
01/16/18
06:26
Technical Analysis
ProShares Short VIX Short-Term Futures: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TYL

Tyler Technologies

$187.95

0.06 (0.03%)

06:25
01/16/18
01/16
06:25
01/16/18
06:25
Recommendations
Tyler Technologies analyst commentary  »

Tyler Technologies price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 26

    Feb

FCAU

Fiat Chrysler

$23.39

-0.03 (-0.13%)

06:25
01/16/18
01/16
06:25
01/16/18
06:25
Periodicals
Fiat Chrysler's Marchionne says new CEO to be named this year, AP reports »

Fiat Chrysler CEO Sergio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$221.23

3.99 (1.84%)

, NTDOY

Nintendo

$50.40

0.69 (1.39%)

06:25
01/16/18
01/16
06:25
01/16/18
06:25
Periodicals
Netflix 'exploring' possibility of launching on Nintendo Switch, Polygon says »

In a statement sent to…

NFLX

Netflix

$221.23

3.99 (1.84%)

NTDOY

Nintendo

$50.40

0.69 (1.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 22

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.